Skip to main content
Valiant Laboratories Limited logo

Valiant Laboratories Limited — Investor Relations & Filings

Ticker · VALIANTLAB ISIN · INE0JWS01017 LEI · 335800VKNJKWJ4LD6855 BSE.NS Manufacturing
Open in API
Filings indexed 173 across all filing types
Latest filing 2025-08-08 Board/Management Inform…
Country IN India
Listing BSE.NS VALIANTLAB

About Valiant Laboratories Limited

https://www.valiantlabs.in/

Valiant Laboratories Limited specializes in the manufacturing of Active Pharmaceutical Ingredients (APIs) and bulk drugs, with a primary focus on the production of Paracetamol. The company operates dedicated manufacturing facilities designed for the large-scale synthesis of analgesic and antipyretic compounds. By maintaining rigorous quality control standards and process efficiencies, it serves as a key supplier for formulations across various therapeutic segments. Its core business activities encompass the chemical processing and distribution of high-grade medicinal ingredients, catering to a diverse range of healthcare manufacturers. The organization prioritizes technical excellence in API synthesis and the optimization of production workflows to ensure a consistent supply of essential pharmaceutical components.

Recent filings

Filing Released Lang Actions
Change in Auditors
Board/Management Information Classification · 95% confidence The document is a formal communication addressed to stock exchanges (BSE and NSE) regarding the outcome of a Board Meeting held on August 8, 2025. It reports two main items: the appointment of a Secretarial Auditor and a change in designation of a Director. The document references compliance with SEBI Listing Regulations and includes annexures with detailed disclosures about these changes. There are no financial statements, earnings data, or comprehensive management discussion of financial results. The document is primarily an announcement of board decisions and changes in management roles, not a full report or financial filing. Therefore, it fits best under the category of Board/Management Information (MANG). The document length (7261 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive disclosure of management changes.
2025-08-08 English
Outcome of Board Meeting
Regulatory Filings
2025-08-08 English
Outcome of Board Meeting
Regulatory Filings
2025-08-08 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-08-05 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) notifying about an upcoming Board Meeting scheduled for August 8, 2025. The purpose of the meeting is to consider and approve the Standalone and Consolidated Audited Financial Results for the quarter ended June 30, 2025. The letter references compliance with SEBI regulations and insider trading rules, and mentions the closure of the trading window. The document does not contain the financial results themselves, nor detailed financial data or analysis. It is an announcement of a future event (Board Meeting) related to financial results approval, not the financial report or results themselves. The document length is short (2548 characters), and it serves as an intimation or notification to the exchanges and public. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and announcement documents that do not contain the actual report or detailed financial data.
2025-08-05 English
Copy of Newspaper Publication
Regulatory Filings
2025-07-24 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.